CareDx
CareDx's revenue rose 13.8% to $380 million in fiscal 2025. Its operating margin was −8.1%, down from 12.2% a year earlier. It paid out $88 million in dividends and buybacks. The diluted share count fell 5.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CareDx does
CareDx makes tests and services for people who have had, or are waiting for, a heart, kidney or lung transplant. Its main products are blood tests that look for signs that the body may be rejecting the new organ without the need for a biopsy. They include AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare and AlloSure Lung. It also sells laboratory products, digital health tools and patient support services.
CareDx earns most of its revenue by running these tests in its own laboratories and billing for them. It says a substantial portion of revenue comes from Medicare. It reports a single segment. Substantially all of its revenue comes from the United States and Europe, and its operations are mainly in the United States and Sweden.
The company is based in Brisbane, California, with other main operations in Omaha, Nebraska and Stockholm, Sweden. It says it has a history of losses and expects more net losses for the next several years.
Its biggest risks, as it describes them
- A substantial share of its revenue comes from Medicare, so lower reimbursement would hurt it badly.
- Its results depend largely on sales of a handful of transplant tests.
- Insurers may drop or limit coverage of its tests, or pay too little for them.
- It has a history of losses and expects more net losses for the next several years.
- Clinicians and medical centers may not adopt its tests, and rivals may keep pace with new technology.
Income statement
CareDx lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 348 | 293 | 235 | 261 | 177 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −348 | −293 | −235 | −261 | −177 |
| Net debt to EBITDA | — | — | — | −4.7x | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −29,726.0x | −9,653.9x | — | — | — |
| Current ratio | 5.6x | 5.1x | 4.0x | 3.9x | 2.9x |
| Quick ratio | 5.4x | 4.8x | 3.8x | 3.7x | 2.6x |
Cash flow
Projections
Project CareDx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought CareDx shares on the open market, and 7 insiders sold $13.6 million, $10.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Jeffrey Adam NovackSecretary and General Counsel | Sold plan | 4,096 | $81.13 | $332,291 | Form 4 |
| Aug 5, 2026 | George BickerstaffDirector | Sold | 20,000 | $46.29 | $925,800 | Form 4 |
| Aug 5, 2026 | Jeffrey Adam NovackSecretary and General Counsel | Sold plan | 2,688 | $46.26 | $124,351 | Form 4 |
| Aug 4, 2026 | Michael GoldbergDirector | Sold | 44,700 | $47.06 | $2.1 million | Form 4 |
| Aug 4, 2026 | Christine CournoyerDirector | Sold plan | 16,000 | $46.94 | $751,040 | Form 4 |
| Jul 16, 2026 | John Walter Hanna JRPresident and CEO, Director | Sold plan | 118,000 | $37.78 | $4.5 million | Form 4 |
| Jul 16, 2026 | Hannah ValantineDirector | Sold plan | 28,779 | $36.14 | $1.0 million | Form 4 |
| Jun 29, 2026 | John Walter Hanna JRPresident and CEO, Director | Sold plan | 39,900 | $29.24 | $1.2 million | Form 4 |
| Jun 26, 2026 | John Walter Hanna JRPresident and CEO, Director | Sold plan | 100 | $29.00 | $2,900 | Form 4 |
| Jun 15, 2026 | John Walter Hanna JRPresident and CEO, Director | Sold plan | 17,683 | $24.03 | $424,922 | Form 4 |
| Jun 15, 2026 | Hannah ValantineDirector | Sold plan | 12,103 | $23.11 | $279,700 | Form 4 |
| Jun 11, 2026 | John Walter Hanna JRPresident and CEO, Director | Sold plan | 21,998 | $24.02 | $528,392 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 8 | 4 of 8 | 4 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | −3.02 | 3.43 | −0.76 |
| Accruals ratio | −34.0% | 3.0% | −14.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 8 | 4 of 8 | 4 of 8 |
Compare
Put CareDx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CareDx | FY25 | 13.8% | −8.1% | — | −20.0% | — | 4 | |
| Castle Biosciences | FY25 | 3.7% | −12.4% | 8.2% | −19.1% | — | 4 | Compare |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | Compare |
| Veracyte | FY25 | 16.0% | 11.2% | 24.5% | 6.1% | −4.6x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 41 | 48 | 77 | 127 | 192 | 296 | 322 | 280 | 334 | 380 |
| Revenue growth | 44.4% | 18.9% | 58.5% | 66.0% | 51.2% | 54.2% | 8.6% | −12.9% | 19.1% | 13.8% |
| Gross profit | 30 | 27 | 44 | 82 | — | — | — | — | — | — |
| Research and development | 12 | 12 | 14 | 31 | 49 | 76 | 90 | 82 | 72 | 71 |
| Operating income | −37 | −20 | −16 | −24 | −22 | −30 | −77 | −203 | 41 | −31 |
| Net income | −40 | −56 | −47 | −22 | −19 | −31 | −77 | −190 | 52 | −21 |
| Diluted EPS (US$) | −2.39 | −2.38 | −1.31 | −0.52 | −0.40 | −0.59 | −1.44 | −3.54 | 0.93 | −0.40 |
| Diluted shares (millions) | 16 | 23 | 36 | 42 | 46 | 52 | 53 | 54 | 57 | 53 |
| Cash flow | ||||||||||
| Cash from operations | −16 | −14 | −4 | −3 | 33 | −19 | −25 | −18 | 38 | 42 |
| Capital expenditure | 0 | 0 | 2 | — | — | — | — | — | — | — |
| Free cash flow | −17 | −14 | −6 | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 28 | 0 | 88 |
| Acquisitions | 21 | 6 | 1 | 18 | 0 | 15 | 1 | 7 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 7 | 22 | 23 | 36 | 47 | 49 | 66 | 35 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 17 | 17 | 65 | 38 | 225 | 348 | 293 | 235 | 261 | 177 |
| Debt incl. finance leases | 24 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 77 | 84 | 131 | 152 | 368 | 567 | 543 | 467 | 491 | 413 |
| Total liabilities | 57 | 90 | 35 | 53 | 91 | 101 | 112 | 206 | 113 | 110 |
| Shareholders' equity | 20 | −6 | 96 | 99 | 278 | 466 | 431 | 261 | 378 | 303 |
| Margins and ratios | ||||||||||
| Gross margin | 74.8% | 55.8% | 56.9% | 64.2% | — | — | — | — | — | — |
| Operating margin | −91.9% | −42.0% | −20.4% | −19.3% | −11.7% | −10.0% | −24.0% | −72.5% | 12.2% | −8.1% |
| Net margin | −97.1% | −114.8% | −61.1% | −17.3% | −9.7% | −10.3% | −23.8% | −67.9% | 15.7% | −5.6% |
| Free cash flow margin | −42.0% | −30.0% | −7.9% | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | 2.4% | −11.1% | 50.6% | — | — | — | — | — | — | — |
| Return on capital | −141.1% | −85.2% | −57.9% | −42.1% | −31.3% | −27.6% | −47.8% | −196.2% | 56.4% | −20.0% |
| Return on equity | −161.2% | −831.1% | −104.1% | −22.5% | −9.9% | −8.2% | −17.1% | −55.0% | 16.4% | −6.3% |
| Return on assets | −59.6% | −69.2% | −43.6% | −15.6% | −7.2% | −6.6% | −13.8% | −37.7% | 11.0% | −4.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | −4.7x | — |